Ronal M. Peralta

Ronal M. Peralta

Auto-generated profile, based on publicly available information

Ronal M. Peralta

Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Science Immunology
Verified
Journal Article
Closed access
BFB. Rhodes Ford
B. Rhodes Ford
PVPaolo D. A. Vignali
Paolo D. A. Vignali
NRNatalie L. Rittenhouse
Natalie L. Rittenhouse
NSNicole Scharping
Nicole Scharping
RPRonal Peralta
Ronal Peralta
APAmanda C. Poholek
Amanda C. Poholek
Response rates to immunotherapy in solid tumors remain low due in part to the elevated prevalence of terminally exhausted T cells, a hypofunctional differentiation state induced through persistent antigen and stress signaling. However, the mechanisms promoting progression to terminal exhaustion in the tumor remain undefined. Using the low-input chromatin immunoprecipitation sequencing method CUT&RUN, we profiled the histone modification landscape of tumor-infiltrating CD8 + T cells throughout differentiation. We found that terminally exhausted T cells had unexpected chromatin features that limit their transcriptional potential. Terminally exhausted T cells had a substantial fraction of active chromatin, including active enhancers enriched for bZIP/AP-1 transcription factor motifs that lacked correlated gene expression, which was restored by immunotherapeutic costimulatory signaling. Reduced transcriptional potential was also driven by an increase in histone bivalency, which we linked directly to hypoxia exposure. Enforced expression of the hypoxia-insensitive histone demethylase Kdm6b was sufficient to overcome hypoxia, increase function, and promote antitumor immunity. Our study reveals the specific epigenetic changes mediated by histone modifications during T cell differentiation that support exhaustion in cancer, highlighting that their altered function is driven by improper costimulatory signals and environmental factors. These data suggest that even terminally exhausted T cells may remain competent for transcription in settings of increased costimulatory signaling and reduced hypoxia.

27 August 2021 in Seminars in Immunology
Verified
Journal Article
Closed access
SZSteven Zhao
Steven Zhao
RPRonal M. Peralta
Ronal M. Peralta
NANatalia Avina-Ochoa
Natalia Avina-Ochoa
GDGreg M. Delgoffe
Greg M. Delgoffe
SKSusan M. Kaech
Susan M. Kaech

19 August 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
CACatarina M. Azevedo
Catarina M. Azevedo
BXBingxian Xie
Bingxian Xie
WGWilliam G. Gunn
William G. Gunn
RPRonal M. Peralta
Ronal M. Peralta
CDCarolina S. Dantas
Carolina S. Dantas
SPSalomé Pinho
Salomé Pinho
T-cell therapies have transformed cancer treatment. Although surface glycans have been shown to play critical roles in regulating T-cell development and function, whether and how the glycome influences T cell–mediated tumor immunity remains an area of active investigation. In this study, we show that the intratumoral T-cell glycome is altered early in human colorectal cancer, with substantial changes in branched N-glycans. We demonstrated that CD8+ T cells expressing β1,6-GlcNAc–branched N-glycans adopted an exhausted phenotype, marked by increased PD1 and Tim3 expression. CRISPR-Cas9 deletion of key branching glycosyltransferase genes revealed that Mgat5 played a prominent role in T-cell exhaustion. In culture-based assays and tumor studies, Mgat5 deletion in CD8+ T cells resulted in improved cancer cell killing. These findings prompted the assessment of whether MGAT5 deletion in anti-CD19 chimeric antigen receptor (CAR) T cells could enable this therapeutic modality in a solid tumor setting. We showed that MGAT5 knockout anti-CD19–CAR T cells inhibited the growth of CD19-transduced tumors. Together, these findings show that MGAT5-mediated branched N-glycans regulate CD8+ T-cell function in cancer and provide a strategy to enhance the antitumor activity of native and CAR T cells.

1 October 2025
Verified
Other
Open access
CACatarina M. Azevedo
Catarina M. Azevedo
BXBingxian Xie
Bingxian Xie
WGWilliam G. Gunn
William G. Gunn
RPRonal M. Peralta
Ronal M. Peralta
CDCarolina S. Dantas
Carolina S. Dantas
SPSalomé Pinho
Salomé Pinho
T-cell therapies have transformed cancer treatment. Although surface glycans have been shown to play critical roles in regulating T-cell development and function, whether and how the glycome influences T cell–mediated tumor immunity remains an area of active investigation. In this study, we show that the intratumoral T-cell glycome is altered early in human colorectal cancer, with substantial changes in branched N-glycans. We demonstrated that CD8+ T cells expressing β1,6-GlcNAc–branched N-glycans adopted an exhausted phenotype, marked by increased PD1 and Tim3 expression. CRISPR-Cas9 deletion of key branching glycosyltransferase genes revealed that Mgat5 played a prominent role in T-cell exhaustion. In culture-based assays and tumor studies, Mgat5 deletion in CD8+ T cells resulted in improved cancer cell killing. These findings prompted the assessment of whether MGAT5 deletion in anti-CD19 chimeric antigen receptor (CAR) T cells could enable this therapeutic modality in a solid tumor setting. We showed that MGAT5 knockout anti-CD19–CAR T cells inhibited the growth of CD19-transduced tumors. Together, these findings show that MGAT5-mediated branched N-glycans regulate CD8+ T-cell function in cancer and provide a strategy to enhance the antitumor activity of native and CAR T cells.

12 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
BFB. Rhodes Ford
B. Rhodes Ford
NRNatalie L. Rittenhouse
Natalie L. Rittenhouse
NSNicole Scharping
Nicole Scharping
PVPaolo D. A. Vignali
Paolo D. A. Vignali
AFAndrew T. Frisch
Andrew T. Frisch
APAmanda C. Poholek
Amanda C. Poholek
Immunotherapy has changed cancer treatment with major clinical successes, but response rates remain low due in part to elevated prevalence of dysfunctional, terminally exhausted T cells. However, the mechanisms promoting progression to terminal exhaustion remain undefined. We profiled the histone modification landscape of tumor-infiltrating CD8 T cells throughout differentiation, finding terminally exhausted T cells possessed chromatin features limiting their transcriptional potential. Active enhancers enriched for bZIP/AP-1 transcription factor motifs lacked correlated gene expression, which were restored by immunotherapeutic costimulatory signaling. Epigenetic repression was also driven by an increase in histone bivalency, which we linked directly to hypoxia exposure. Our study is the first to profile the precise epigenetic changes during intratumoral differentiation to exhaustion, highlighting their altered function is driven by both improper costimulatory signals and environmental factors. These data suggest even terminally exhausted T cells remain poised for transcription in settings of increased costimulatory signaling and reduced hypoxia.